All In Biotech

Drug Trial Radar · NCT01486797

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Last checked: Nov 19, 2026Latest source record: May 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Mar 2012

Primary completion

Nov 2014

Study completion Apr 2017

Sponsor

Lead sponsor
TME Pharma AGIndustry
Sponsor type
Industry
First posted
Dec 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously treated patients with chronic lymphocytic leukemia (CLL).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • NOX-A12Drug

    Pilot Group (NOX-A12 single agent, and combined with BR): * 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose. Expansion Group (NOX-A12 in combination with BR): * Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of NOX A12 alone and in combination with BR.Time frame: 30 months
  2. Complete remission (CR) rateTime frame: 6 months

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical University Innsbruck, Division of Hematology and Oncology

    Innsbruck, Austria

  • University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology

    Salzburg, Austria

  • Landeskrankenhaus Steyr, Department of Internal Medicine II (Hematology and Oncology)

    Steyr, Austria

  • Hospital Wels-Grieskrichen, Department of Internal Medicine IV (Hematology and Oncology)

    Wels, Austria

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Institute Jules Bordet, Department of Hematology

    Brussels, Belgium

  • University Hospital Gasthuisberg, Department of Hematology

    Leuven, Belgium

  • Centre Hospitalier Universitaire Clémenceau, Department of Hematology

    Caen, France

  • Hospices Civils, Department of Hematology

    Lyon, France

  • Centre Hospitalier Universitaire de la Milétrie, Department of Hematology

    Poitiers, France

  • University Hospital, Institute of Hematology and Oncology

    Bologna, Italy

  • Azienda Sanitaria Locale 8, Department of Oncology

    Cagliari, Italy

  • University Hospital San Martino, Department of Hematology and Oncology

    Genova, Italy

  • Niguarda Ca'Granda Hospital

    Milan, Italy

  • University Scientific Research Institute San Raffaele

    Milan, Italy

  • University School of Medicine, Department of Hematology

    Padova, Italy

  • University La Sapienza, Department of Cellular Biotechnologies and Hematology

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.